^
    Back
    Association details:
    Biomarker:RXRA overexpression
    Cancer:Chronic Myeloid Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASH 2022
    Title:

    4317 Rxra Overexpression Improves the Sensitivity to Imatinib In-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells

    Published date:
    11/03/2022
    Excerpt:
    Further RXRA OE also led to an increased response to IM in-vivo, which resulted in better survival than IM-treated EV mice (Median survival 57 vs 48 days)….In conclusion, we have identified that enforced expression of RXRA in CML cells improved sensitivity to TKI in-vitro and in-vivo.
    DOI:
    https://doi.org/10.1182/blood-2022-168634